Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 14/20 | 0.72 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19946143 | 0.90 | AAK1 (0.61) | AAK1ROCK2 | |
| SCHEMBL16982708 | 0.87 | AAK1 (0.55) | AAK1ROCK2DYRK1A | |
| SCHEMBL15455095 | 0.84 | AAK1 (0.52) | AAK1DYRK1AMKNK2 | |
| SCHEMBL15455097 | 0.84 | AAK1 (0.52) | AAK1DYRK1AMKNK2 | |
| SCHEMBL20176304 | 0.84 | AAK1 (1.00) | AAK1 | |
| SCHEMBL15458779 | 0.82 | ROCK2 (0.53) | AAK1ROCK2DYRK1A | |
| SCHEMBL15458848 | 0.82 | ROCK2 (0.49) | AAK1ROCK2DYRK1A | |
| SCHEMBL15458770 | 0.81 | AAK1 (0.55) | AAK1ROCK2DYRK1A | |
| SCHEMBL15458825 | 0.81 | AAK1 (0.47) | AAK1ROCK2DYRK1A | |
| SCHEMBL19946144 | 0.81 | AAK1 (0.59) | AAK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | AAK1, NCK1, ADCK1 | AAK1 1/4885ROCK2 966/4885DYRK1A 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.